Press Releases
Page 5 • 12 itemsAccess critical pharma & biotech press releases. Stay ahead on drug approvals, clinical trials, M&A, and regulatory updates impacting global markets.
Immunic Appoints Dr. Michael Panzara as Chief Medical Officer to Lead Vidofludimus Calcium Development
Immunic Inc. names multiple sclerosis drug development expert Dr. Michael Panzara as CMO to advance Vidofludimus Calcium through pivotal trials.
Zhengye Biotechnology Reports Fiscal 2025 Financial Results for Veterinary Vaccine Business
Zhengye Biotechnology (NASDAQ: ZYBT) announces fiscal year 2025 financial results, highlighting performance in veterinary vaccine manufacturing and research operations.
Akso Health Group Launches Brain-Computer Interface R&D Program Targeting Neurotechnology Market
Akso Health Group (NASDAQ: AHG) announces entry into brain-computer interface development, establishing R&D infrastructure for next-generation neurotechnology solutions.
Evofem Biosciences Secures Exclusive SOLOSEC Distribution Agreement for Sub-Saharan Africa Market
Evofem Biosciences announces exclusive distribution deal for SOLOSEC (secnidazole) in Sub-Saharan Africa, expanding access to FDA-approved treatment.
PSG 2026 Specialty Drug Benefits Report: Cost Management Remains Top Priority as Coverage Strategies Challenge Payers
PSG's 13th annual report reveals payers prioritize cost management while struggling with coverage strategies for new specialty drugs and indications.
WuXi AppTec Reports 39.4% Revenue Growth in Q1 2026, Backlog Reaches RMB 59.77 Billion
WuXi AppTec delivers strong Q1 2026 results with 39.4% revenue growth and 71.7% profit increase, signaling robust pharmaceutical outsourcing demand.
IMG Pharma Acquires Matsumoto Pharmaceutical in Strategic Japanese Market Expansion Deal
IMG Pharmaceutical announces definitive agreement to acquire Matsumoto Pharmaceutical, expanding its presence in Japan's pharmaceutical manufacturing market.
Aquestive Therapeutics Faces Class Action Lawsuit Over Anaphylm Drug Approval Timeline Claims
Investors file class action against Aquestive Therapeutics alleging misleading statements about Anaphylm sublingual film approval timeline and January 2026 PDUFA date.
BioMarin Completes $3 Billion Acquisition of Amicus Therapeutics, Expands Rare Disease Portfolio with Galafold and Pompe Therapies
BioMarin's acquisition of Amicus adds globally approved Galafold for Fabry disease and POMBILITI/OPFOLDA combination for Pompe disease to its rare disease pipeline.
Eyebright Medical Reports Strong 2025 Results Driven by Innovation and Global Expansion
Eyebright Medical Technology releases 2025 annual and sustainability reports showing strong performance amid industry policy adjustments and global expansion.
PMC Organometallix Announces 10-25% Price Increases Across All Product Lines Effective May 2026
PMC Organometallix will implement 10-25% price increases on all products globally starting May 1, 2026, citing significant market condition changes.
Sunnybrook Health Sciences Centre Receives $41 Million Investment to Expand Clinical Trials Infrastructure in Canada
Sunnybrook Health Sciences Centre announces $41M philanthropic investment to expand clinical trials capacity and strengthen Canada's position in global research.